Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00460-4/fulltext
Thursday, December 16, 2021